ESTRO 2023 - Abstract Book

S869

Digital Posters

ESTRO 2023

was 51.8 years [19-91] with a sex ratio of 1. The most frequent localizations were Nasopharynx (7 patients; 23.3%), Breast (6 patients; 20%), and Lung (6 patients; 20%). Seventeen patients (56,7%) were housed at home at the time of the questionnaire. Most patients had good general condition with a mean Kranfoskey performance status (KPS) of 85% [50 100%]. Eight patients (26.6%) already had sleep disorders before diagnosis. Eleven patients (36.7%) had surgery and 23 (76.7%) had chemotherapy. Fisher exact test was performed to compare patients with or without sleep disorders regarding these different parameters: Sex; Surgery; Chemotherapy; Hosting; Physical concerns; Emotional concerns; Social concerns; Practical concerns; Spiritual concerns.

Results Thirteen patients (43.3%) had sleep disorders.

None of the factors studied were associated with sleep disorders (Table). Sleep disorders (Yes) p Male Female 50% 50% 1

Surgery No surgery

37.5% 62.5%

1

Chemotherapy No chemotherapy Hosting one Home Another hosting Physical concerns No physical concerns Emotional concerns No emotional concerns Social concerns No social concerns Practical concerns No practical concerns Spiritual concerns No spiritual concerns

75% 25%

1

37.5% 62.5% 62.5% 37.5% 85.5% 15.5%

0.24

1

0.09

50% 50%

1

62.5% 37.5% 37.5% 62.5%

0.68

1

Conclusion Sleep disorders are a common problem in cancer patients during treatment.

The evaluation of this disorder must be carried out in our clinical routine given their incidence (43.3%). The absence of pre-predictive factors for the occurrence of these suggests the necessity to assess them for all patients. A better assessment of factors associated with sleep disorders needs the realization of larger series.

PO-1086 Compliance analysis in a phase III study of esophagus-sparring palliative spine irradiation.

A. Mann Nielsen 1 , K. Smedegaard Storm 2 , M. Hiul Suppli 3 , A.C. Lund 3 , C. Behrens 1 , P. Sibolt 1 , H. Pappot 3 , I. Richter Vogelius 3 , G. Persson 1 1 Copenhagen University Hospital – Herlev and Gentofte, Department of Oncology, Copenhagen, Denmark; 2 Copenhagen University Hospital – Herlev and Gentofte, Department of Oncology, Copenhagen, Denmark; 3 Copenhagen University Hospital – Rigshospitalet, Department of Oncology, Copenhagen, Denmark Purpose or Objective The ESO-SPARE trial investigates if esophagus sparring radiotherapy (RT) can reduce patient reported esophagitis in patients with cervical and thoracic metastatic spinal cord compression (MSCC). As the patient cohort is fragile, a considerable drop out was expected. An interim analysis of patient’s adherence to protocol and drop-out rate was planned as a quality assurance of the sample estimation. Materials and Methods In ESO-SPARE (ClinicalTrials.gov Identifier: NCT05109819) patients are randomized to standard or esophagus sparing volumetric modulated radiotherapy in any fractionation. In the experimental arm, esophagus dose may not to exceed a certain biological equivalent dose (EQD2 < 8 Gy, α / β =3) and this is prioritized higher than CTV and PTV coverage. Follow-up (FU) consists exclusively of Patient Reported Outcomes (PROs). The symptoms dysphagia, nausea, dyspepsia, and pain are reported daily for 5 weeks and weekly for additional 4 weeks by PRO-CTCAE. Use of analgesics, weight, and quality of life (EQD-5 and EORTC QLQ C30 questionnaires) are reported weekly for 9 weeks. Patients are included by radiotherapy technologists or physicians. Only patients deemed fit to complete 9 weeks FU are included in the study. Co-primary endpoints are 1) severity of dysphagia, reported as the maximum PRO-CTC-AE score in the 5 weeks after treatment start and 2) ambulatory function at 9 weeks, assessed from EQ-5D questionnaires. A total of 200 patients from two centers are planned. To meet power calculations 62 patients in each arm are needed.